Life science start-up Avro experiments with alternative medication delivery with an adhesive skin patch. Similar to the nicotine version, the innovation is expected to release allergy medications in a consistent manner to fight the effects of seasonal factors among children and the elderly.
The alternative medication delivery is convenient and fuss-free, however, it is still in its testing stages and not approved for human use. Aside from implications about allergies, Avro is also planning to expand the reach of its product to include other medical conditions that need consistent availability of meds.
Being able to deliver the needed drugs via a patch also alleviates the stress of having to swallow bitter pills or having to endure injections.
Photo Credits: Shutterstock
Skin Patch Medication Deliveries
Avro Sets Out to Deliver Allergy Medication Through the Skin
Trend Themes
1. Alternative Medication Delivery - Avro's adhesive skin patch offers an alternative way of delivering medication, potentially disrupting traditional pill and injection methods.
2. Consistent Medication Release - The skin patch provides consistent release of allergy medications, allowing for more effective treatment of seasonal factors among children and the elderly.
3. Expansion to Other Medical Conditions - Avro plans to expand its skin patch product to include other medical conditions that require consistent availability of medication, creating opportunities for disruptive innovation in various healthcare fields.
Industry Implications
1. Pharmaceuticals - The alternative medication delivery system offered by Avro's skin patch could disrupt traditional methods of pharmaceutical delivery.
2. Healthcare - The consistent medication release provided by the skin patch has the potential to revolutionize healthcare treatments, particularly for allergies and other medical conditions.
3. Medical Devices - Avro's adhesive skin patch falls under the medical devices industry, offering a disruptive innovation in drug delivery methods.